A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

被引：1
|
作者：
Rovithi, Maria
Labots, Marlette
Richard
Honeywell
Ten Tije, Albert J.
Ruijter, Rita
Skardhamar, Mikkjal
Peters, Godefridus J.
Voortman, Jens
Verheul, Henk M. W.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2591
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2591
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
    Jones, S. F.
    Plummer, E. R.
    Burris, H. A.
    Razak, A. R.
    Meluch, A. A.
    Bowen, C. J.
    Williams, D. H.
    Hodge, J. P.
    Dar, M. M.
    Calvert, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
  • [23] Phase Ib study of afatinib plus standard-dose cetuximab in patients (pts) with advanced solid tumors.
    Gazzah, Anas
    Boni, Valentina
    Soria, Jean-Charles
    Holgado, Esther
    Even, Caroline
    Kaci, Mahmoud Ould
    Nazabadioko, Serge
    Xue, Wenqiong
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors.
    Shepard, Dale Randall
    Bruce, Justine Yang
    Garrido-Laguna, Ignacio
    Rosbrook, Brad
    Martini, Jean-Francols
    Plthavala, Yazdi K.
    Valota, Olga
    Michaelson, M. Dror
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Thery, Jean Christophe
    Faivre, Laura
    Le Deley, Marie-Cecile
    Paci, Angelo
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Poinsignon, Vianney
    Malekzadeh, Katty
    Ribrag, Vincent
    Angevin, Eric
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos Alberto
    Gharib, Myriam
    Dufour, Fabienne
    Soria, Jean-Charles
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Phase I study of MEDI0639 in patients with advanced solid tumors.
    Falchook, Gerald Steven
    Dowlati, Afshin
    Naing, Aung
    Gribbin, Matthew Joseph
    Jenkins, David William
    Chang, Linda L.
    Lai, Dominic W.
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A phase I study sunitinib malate (S) and gemcitabine (G) in solid tumors.
    Krishnamurthi, S. S.
    Rath, L.
    Bokar, J. A.
    Dowlati, A.
    Savvides, P.
    Gibbons, J.
    Cooney, M. M.
    Meropol, N. J.
    Ivy, S. P.
    Brell, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [29] Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Kwak, Eunice Lee
    Cleary, James M.
    Tolaney, Sara
    Gandhi, Leena
    Clark, Jeffrey W.
    Wolanski, Andrew
    Frame, Sheelagh
    Rodig, Scott J.
    Chiao, Judy H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors.
    Zucali, P. A.
    Simonelli, M.
    De Vincenzo, F.
    Lorenzi, E.
    Rimassa, L.
    Balzarini, L.
    Quagliuolo, V.
    Lambiase, A.
    Bordignon, C.
    Santoro, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345